Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relivar
- Development stage
- Unknown
- Lead developer
- IntelGenx
- Modality
- Small Molecules
- Administration
- Buccal
01
Overview
Relivar is a novel buccal formulation of dronabinol, a synthetic cannabinoid, developed by IntelGenx using its proprietary mucoadhesive AdVersa buccal delivery technology. It is intended for the treatment of various diseases, including neuropathic pain and nausea. IntelGenx acquired full ownership and development rights for Relivar through a series of agreements with partners like Cary Pharmaceuticals, Cannasat Therapeutics, and Cynapsus Therapeutics, aiming to streamline its development and commercialization.
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Relivar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Relivar.